Catalog No.
DHF46301
Expression system
Mammalian Cells
Species reactivity
Human
Host species
Human
Isotype
IgG4-lambda
Clonality
Monoclonal
Applications
Research Grade Biosimilar
Target
Glioblastoma-derived T-cell suppressor factor, TGF-beta-2, LAP, G-TSF, TGFB2, Cetermin, Transforming growth factor beta-2 proprotein
Concentration
5.46 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
P61812
Form
Liquid
Storage buffer
PBS, pH 7.4 with 0.2M Arg
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names
CAT-152, Trabio, CAS: 285985-06-0
Clone ID
Lerdelimumab
Note
For research use only. Not suitable for clinical or therapeutic use.
Lerdelimumab., PMID:12001808
TGF-beta2-induced matrix modification and cell transdifferentiation in the human lens capsular bag., PMID:12091431
Technology evaluation: lerdelimumab, Cambridge Antibody Technology., PMID:12772512
Gateways to clinical trials., PMID:12808477
Evaluation of anti-TGF-beta2 antibody as a new postoperative anti-scarring agent in glaucoma surgery., PMID:12882787
Large- and small-molecule inhibitors of transforming growth factor-beta signaling., PMID:16784021
Short-term exposure to transforming growth factor beta induces long-term fibrotic responses., PMID:16934251
Factors affecting the outcome of trabeculectomy: an analysis based on combined data from two phase III studies of an antibody to transforming growth factor beta2, CAT-152., PMID:17719641
A phase III study of subconjunctival human anti-transforming growth factor beta(2) monoclonal antibody (CAT-152) to prevent scarring after first-time trabeculectomy., PMID:17908591
CAT-152 Trabeculectomy Study., PMID:17908596
Trabeculectomy outcomes., PMID:18519074
TGF-beta(2) antibody in trabeculectomy., PMID:19118706
Strategies for TGF-beta modulation: a review of recent patents., PMID:19939191
Study protocol: the TRAnsplant BIOpsies (TRABIO) study - a prospective, observational, multicentre cohort study to assess the treatment of kidney graft rejections., PMID:35450886
Trabeculectomy outcomes, PMID: 18519074
TGF-beta2-induced matrix modification and cell transdifferentiation in the human lens capsular bag, PMID: 12091431
TGF-beta(2) antibody in trabeculectomy, PMID: 19118706
Technology evaluation: lerdelimumab, Cambridge Antibody Technology, PMID: 12772512
Strategies for TGF-beta modulation: a review of recent patents, PMID: 19939191
Short-term exposure to transforming growth factor beta induces long-term fibrotic responses, PMID: 16934251
Lerdelimumab, PMID: 12001808
Large- and small-molecule inhibitors of transforming growth factor-beta signaling, PMID: 16784021
Gateways to clinical trials, PMID: 12808477
Factors affecting the outcome of trabeculectomy: an analysis based on combined data from two phase III studies of an antibody to transforming growth factor beta2, CAT-152, PMID: 17719641
Evaluation of anti-TGF-beta2 antibody as a new postoperative anti-scarring agent in glaucoma surgery, PMID: 12882787
CAT-152 Trabeculectomy Study, PMID: 17908596
A phase III study of subconjunctival human anti-transforming growth factor beta(2) monoclonal antibody (CAT-152) to prevent scarring after first-time trabeculectomy, PMID: 17908591
For research use only. Not for human or drug use.
